Axicabtagene ciloleucel: The first FDA-approved CAR T-cell therapy for relapsed/refractory large B-cell lymphoma Review
| Authors: | King, A. C.; Orozco, J. S. |
| Review Title: | Axicabtagene ciloleucel: The first FDA-approved CAR T-cell therapy for relapsed/refractory large B-cell lymphoma |
| Abstract: | Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy in relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients who have had suboptimal responses to conventional therapies. The immune activation that confers the efficacy of axi-cel comes at the price of potentially devastating adverse phenomena: cytokine release syndrome and neurotoxicity. This article serves as an overview of axi-cel, including a review of the available clinical evidence, mechanism of action, and management of some of the unique toxicities of axi-cel. |
| Keywords: | united states food and drug administration; neoplasm recurrence, local; disease management; treatment outcomes; immunotherapy -- methods; lymphoma, b-cell -- therapy; immunotherapy -- adverse effects; systemic inflammatory response syndrome -- risk factors; neurotoxicity syndromes -- risk factors |
| Journal Title: | Journal of the Advanced Practitioner in Oncology |
| Volume: | 10 |
| Issue: | 8 |
| ISSN: | 2150-0878 |
| Publisher: | Harborside Press |
| Date Published: | 2019-11-01 |
| Start Page: | 878 |
| End Page: | 882 |
| Language: | English |
| ACCESSION: | 140086675 |
| DOI: | 10.6004/jadpro.2019.10.8.9 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| PMCID: | PMC7517758 |
| PUBMED: | 33425471 |
| DOI/URL: | |
| Notes: | Source: cin20 |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work